What You Should Know:
- ConcertAI, a developer of AI-powered healthcare solutions, announced today the acquisition of CancerLinQ, a subsidiary of the American Society of Clinical Oncology (ASCO).
- This strategic move will significantly enhance and expand CancerLinQ's capabilities, unlocking the potential of real-world data and next-generation AI to revolutionize cancer care and accelerate clinical research.
CancerLinQ Background
CancerLinQ represents one of the largest oncology
Read More
CancerLinQ
Biden Admin Builds on Cancer Moonshot with 13 More Initiatives
What You Should Know:
- One year ago, President Joe Biden and First Lady Jill Biden reignited the Cancer Moonshot, setting an ambitious, achievable goal: to reduce the death rate from cancer by at least 50 percent over the next 25 years, and improve the experience of people and families living with and surviving cancer, ultimately ending cancer as we know it today.
- The Cancer Moonshot has spurred tremendous action across the federal government and from the public and private
Read More
To Advance Health Equity, Put Real-World Cancer Data to Work
Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons — like institutional racism and poverty — are a reflection of our broader society. Other inequities may go unrecognized but are no less damaging. People with underlying health conditions, for example, may be excluded from clinical trials, preventing them from accessing leading-edge treatments and limiting the evidence available to guide their care.
With multiple drivers of
Read More
TeraRecon Acquired by SymphonyAI: What is the Impact for Medical Imaging Market?
On the 4th March 2020, TeraRecon announced it had signed an agreement to be acquired by the SymphonyAI Group. Here are the facts of the deal, followed by our take on the potential impact on the medical imaging market:
- The terms of the deal were not disclosed and TeraRecon will continue to operate business as usual. However, it will benefit from greater financial backing and the synergistic technologies from other companies in the Group’s portfolio.
- TeraRecon is an Advanced
Read More
Data-Driven Precision Medicine Startup Tempus Lands $200M to Expand Into New Therapeutic Areas
Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an additional $200M financing at a value of $3.1 billion dollars. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth, and funds and accounts managed by T. Rowe Price. With this latest round, the company has raised $520 million since its founding in September 2015.Founded in 2015, Tempus has the largest
Read More
Pfizer & Concerto HealthAI Team Up on Precision Oncology Collaboration
Concerto HealthAI announced a deal
with Pfizer, through which Pfizer will
harness Concerto HealthAI’s eurekaHealth AI platform
and real-world data (RWD) to help identify new and more precise treatment
options as well as accelerate completion times for various outcomes studies. Concerto
HealthAI is comprised of the leading healthcare data scientists, health
economists, epidemiologists, and AI software engineers to advance flexible and
increasingly enterprise grade solutions for advancing RWE into
Read More
SAP Purchases $18M Worth of Stock into Castlight Health
SAP has purchased purchased 4.76 million shares of newly issued Class B common stock in Castlight Health, a leading health benefits platform provider. The purchase results in SAP holding 4.7% post-issuance of the currently-outstanding common shares of Castlight, at a price per share of $3.77, for approximately $18 million in cash. SAP also received a warrant in connection with its stock purchase, under which SAP has the right to purchase an additional 1.9 million shares of Castlight Health Class
Read More
